The NLRP3 inflammasome and stroke

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 4, 2015, Pages 4787-4794

  Tong, Yeqing ^a,b   Ding, Zhi Hong ^c   Zhan, Fa Xian ^a   Cai, Li ^d   Yin, Xiaoxv ^b   Ling, Jin Lian ^f   Ye, Jian Jun ^a   Hou, Shuang Yi ^a   Lu, Zuxun ^b   Wang, Zhi Hong ^e   Liu, Jia Fa ^a  

^a Hubei Center for Animal Disease Control and Prevention   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Xiangyang Hospital of Traditional Chinese Medical Hospital   (China)

^d Wuhan Centers for Disease Prevention and Control   (China)

^e THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Inflammasome; Inflammation; NLRP3; Stroke

Indexed keywords

ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; MYELOID DIFFERENTIATION FACTOR 88;

ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; ENDOTHELIAL DYSFUNCTION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; PROTEIN EXPRESSION; REVIEW;

EID: 84931275610     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. [1] Donnan GA, Fisher M, Macleod M and Davis SM. Stroke. Lancet 2008; 371: 1612-23.
2. [2] Rothwell PM, Algra A and Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011; 377: 1681-92.
3. [3] Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF; American Heart Association/American Stroke Association Stroke Council; American Heart Association/American Stroke Association Clinical Cardiology Council; American Heart Association/American Stroke Association Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease Working Group; Quality of Care Outcomes in Research Interdisciplinary Working Group. Guidelines for the early management of adults with ischemic stroke: a guideline from the american heart association/american stroke association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655-711.
4. [4] Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O’Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet 2014; 383: 245-54.
5. [5] Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet 2014; 383: 970-83.
6. [6] Humphries SE and Morgan L. Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol 2004; 3: 227-35.
7. [7] Dichgans M. Genetics of ischaemic stroke. Lancet Neurol 2007; 3: 149-61.
8. [8] Bevan S and Markus HS. Genetics of common polygenic ischaemic stroke: current understanding and future challenges. Stroke Res Treat 2011; 2011: 179061.
9. [9] Li L, Guo Y, Chen Z, Chen J and Peto R. Epidemiology and the control of disease in china, with emphasis on the chinese biobank study. Public Health 2012; 126: 210-3.
10. [10] Ke Q. Neurology and neurologic practice in China. Neurology 2012; 78: 683-4.
11. [11] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O’Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
12. [12] Bova IY, Bornstein NM and Korczyn AD. Acute infection as a risk factor for ischemic stroke. Stroke 1996; 27: 2204-6.
13. [13] Grau AJ, Buggle F, Becher H, Zimmermann E, Spiel M, Fent T, Maiwald M, Werle E, Zorn M, Hengel and Hacke W. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. Neurology 1998; 50: 196-203.
14. [14] Khan M and Qureshi AI. Factors associated with increased rates of post-procedural stroke or death following carotid artery stent placement: a systematic review. J Vasc Interv Neurol 2014; 7: 11-20.
15. [15] Wilson SH, Caplice NM, Simari RD, Holmes DR Jr, Carlson PJ, Lerman A. Activated nuclear factor-kappab is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 2000; 148: 23-30.
16. [16] Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
17. [17] Arenillas JF and Alvarez-Sabin J. Basic mechanisms in intracranial large-artery atherosclerosis: advances and challenges. Cerebrovasc Dis 2005; 20 Suppl 2: 75-83.
18. [18] Jain MK, Sangwung P and Hamik A. Regulation of an inflammatory disease: kruppel-like factors and atherosclerosis. Arterioscler Thromb Vasc Biol 2014; 34: 499-508.
19. [19] Macko RF, Ameriso SF, Barndt R, Clough W, Weiner JM, Fisher M. Precipitants of brain infarction. Roles of preceding infection/inflammation and recent psychological stress. Stroke 1996; 27: 1999-2004.
20. [20] Bitzur R, Harats D and Rubinstein A. [Guidelines for the prevention and treatment of atherosclerosis and cardiovasculer diseases: treatment of diabetes mellitus, dyslipidemia and the prevention of stroke]. Harefuah 2005; 144: 647-54.
21. [21] Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G. Atherosclerosis as an inflammatory disease. Curr Pharm Des 2012; 18: 4266-88.
22. [22] Martinon F, KBurns K and Tschopp J. The Inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proil-beta. Mol Cell 2002; 10: 417-26.
23. [23] Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, Flavell RA, Girardin SE, Godzik A, Harton JA, Hoffman HM, Hugot JP, Inohara N, Mackenzie A, Maltais LJ, Nunez G, Ogura Y, Otten LA, Philpott D, Reed JC, Reith W, Schreiber S, Steimle V, Ward PA. The NLR gene family: a standard nomenclature. Immunity 2008; 28: 285-7.
24. [24] Schroder K and Tschopp J. The inflammasomes. Cell 2010; 140: 821-32.
25. [25] Dowling JK and O’Neill LA. Biochemical regulation of the inflammasome. Crit Rev Biochem Mol Biol 2012; 47: 424-43.
26. [26] Menu P and Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol 2011; 166: 1-15.
27. [27] Inoue Y, Shirasuna K, Kimura H, Usui F, Kawashima A, Karasawa T, Tago K, Dezaki K, Nishimura S, Sagara J, Noda T, Iwakura Y, Tsutsui H, Taniguchi S, Yanagisawa K, Yada T, Yasuda Y, Takahashi M. NLRP3 regulates neutrophil functions and contributes to hepatic ischemia-reperfusion injury independently of inflammasomes. J Immunol 2014; 192: 4342-51.
28. [28] Garg NJ. Inflammasomes in cardiovascular diseases. Am J Cardiovasc Dis 2011; 1: 244-54.
29. [29] Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 1: 1357-61.
30. [30] Zhou R, Tardivel A, Thorens B, Choi I and Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 1: 136-40.
31. [31] Yang F, Wang Z, Wei X, Han H, Meng X, Zhang Y, Shi W, Li F, Xin T, Pang Q, Yi F. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J Cereb Blood Flow Metab 2014; 34: 660-7.
32. [32] Fann DY, Lee SY, Manzanero S, Tang SC, Gelderblom M, Chunduri P, Bernreuther C, Glatzel M, Cheng YL, Thundyil J, Widiapradja A, Lok KZ, Foo SL, Wang YC, Li YI, Drummond GR, Basta M, Magnus T, Jo DG, Mattson MP, Sobey CG, Arumugam TV. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis 2013; 4: e790.
33. [33] Xie Q, Shen WW, Zhong J, Huang C, Zhang L, Li J. Lipopolysaccharide/adenosine triphosphate induces IL-1β and IL-18 secretion through the NLRP3 inflammasome in RAW264.7 murine macrophage cells. Int J Mol Med 2014; 34: 341-9.
34. [34] Hua KF, Yang SM, Kao TY, Chang JM, Chen HL, Tsai YJ, Chen A, Yang SS, Chao LK, Ka SM. Osthole mitigates progressive IgA nephropathy by inhibiting reactive oxygen species generation and Nf-Kappab/NLRP3 pathway. PLoS One 2013; 8: e77794.
35. [35] Palová-Jelínková L, Dáňová K, Drašarová H, Dvořák M, Funda DP, Fundová P, Kotrbová-Kozak A, Černá M, Kamanová J, Martin SF, Freudenberg M, Tučková L. pepsin digest of wheat gliadin fraction increases production of IL-1βvia Tlr4/Myd88/Trif/Mapk/Nf-Kappab signaling pathway and an NLRP3 inflammasome activation. PLoS One 2013; 8: e62426.
36. [36] Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WG, Kaneko H, Fowler BJ, Bogdanovich S, Albuquerque RJ, Hauswirth WW, Chiodo VA, Kugel JF, Goodrich JA, Ponicsan SL, Chaudhuri G, Murphy MP, Dunaief JL, Ambati BK, Ogura Y, Yoo JW, Lee DK, Provost P, Hinton DR, Núñez G, Baffi JZ, Kleinman ME, Ambati J. DICER1 loss and alu rna induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 2012; 149: 847-59.
37. [37] Segovia J, Sabbah A, Mgbemena V, Tsai SY, Chang TH, Berton MT, Morris IR, Allen IC, Ting JP, Bose S. TLR2/MyD88/Nf-kB pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection. PLoS One 2012; 7: e29695.
38. [38] Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA and Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-90.
39. [39] McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, Beck PL, Muruve DA, Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010; 330: 362-6.
40. [40] Artlett CM. The role of the NLRP3 inflammasome in fibrosis. Open Rheumatol J 2012; 6: 80-6.
41. [41] Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H, Wright JR Jr, Macdonald JA, Lees-Miller JP, Roach D, Semeniuk LM, Duff HJ. The NLRP3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β. Exp Physiol 2013; 98: 462-72.
42. [42] Pelegrin P and Surprenant A. Dynamics of macrophage polarization reveal new mechanism to inhibit 1L-1beta release through pyrophosphates. EMBO J 2009; 28: 2114-27.
43. [43] Qin M, Pirouz A, Kim MH, Krutzik SR, Garbán HJ, Kim J. Propionibacterium acnes induces IL-1βsecretion via the NLRP3 inflammasome in human monocytes. J Invest Dermatol 2014; 134: 381-8.
44. [44] Zheng F, Xing S, Gong Z, Xing Q. NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis. Heart Lung Circ 2013; 22: 746-50.
45. [45] de Nooijer R, von der Thüsen JH, Verkleij CJ, Kuiper J, Jukema JW, van der Wall EE, van Berkel JC, Biessen EA. Overexpression of 1L-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apoli poprotein-E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 2313-9.
46. [46] Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, Eisenbarth SC, Florquin S, Flavell RA, Leemans JC, Sutterwala FS. Necrotic cells trigger a sterile inflammatory response through the NLRP3 inflammasome. Proc Natl Acad Sci U S A 2009; 106: 20388-93.
47. [47] Zuurbier CJ, Jong WM, Eerbeek O, Koeman A, Pulskens WP, Butter LM, Leemans JC, Hollmann MW. Deletion of the innate immune NLRP3 receptor abolishes cardiac ischemic preconditioning and is associated with decreased Il-6/STAT signaling. PLoS One 2012; 7: e40643.
48. [48] Ataide MA, Andrade WA, Zamboni DS, Wang D, Souza Mdo C, Franklin BS, Elian S, Martins FS, Pereira D, Reed G, Fitzgerald KA, Golenbock DT, Gazzinelli RT. Malaria-Induced NLRP12/NLRP3-dependent caspase-1 activation mediates inflammation and hypersensitivity to bacterial superinfection. PLoS Pathog 2014; 10: e1003885.
49. [49] Gurung P, Anand PK, Malireddi RK, Vande Walle L, Van Opdenbosch N, Dillon CP, Weinlich R, Green DR, Lamkanfi M, Kanneganti TD. Fadd and caspase-8 mediate priming and activation of the canonical and noncanonical NLRP3 inflammasomes. J Immunol 2014; 192: 1835-46.
50. [50] Li X and Zhong F. Nickel induces interleukin-1beta secretion via the NLRP3-asc-caspase-1 pathway. Inflammation 2014; 37: 457-66.
51. [51] Xu JF, Washko GR, Nakahira K, Hatabu H, Patel AS, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, Estépar RS, Diaz AA, Li HP, Qu JM, Himes BE, Come CE, D’Aco K, Martinez FJ, Han MK, Lynch DA, Crapo JD, Morse D, Ryter SW, Silverman EK, Rosas IO, Choi AM, Hunninghake GM; COPDGene Investigators. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 2012; 185: 547-56.
52. [52] McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P and McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007; 66: 1683-4.
53. [53] Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T; CANTOS Pilot Investigative Group. Effects of interleukin-1βinhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012; 126: 2739-48.
54. [54] Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162: 597-605.
55. [55] Carne X. [Canakinumab, a monoclonal antibody against il-1beta, with potential utility in different inflammatory processes]. Med Clin (Barc) 2011; 136 Suppl 1: 34-7.
56. [56] Satoh M, Tabuchi T, Itoh T, Nakamura M. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin. Clin Sci (Lond) 2014; 126: 233-41.
57. [57] Lopez-Castejon G and Pelegrin P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs 2012; 21: 995-1007.
58. [58] Stokes L, Jiang LH, Alcaraz L, Bent J, Bowers K, Fagura M, Furber M, Mortimore M, Lawson M, Theaker J, Laurent C, Braddock M, Surprenant A. Characterization of a selective and potent antagonist of human P2X (7) receptors, AZ11645373. Br J Pharmacol 2006; 149: 880-7.
59. [59] Arulkumaran N, Unwin RJ and Tam FW. A potential therapeutic role for P2X7 Receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs 2011; 20: 897-915.
60. [60] Tuttolomondo A, Di Sciacca R, Di Raimondo D, Renda C, Pinto A, Licata G. inflammation as a therapeutic target in acute ischemic stroke treatment. Curr Top Med Chem 2009; 9: 1240-60.
61. [61] Turner R and Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Drug News Perspect 2007; 20: 221-6.
62. [62] DeGraba TJ. Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation. Stroke 2004; 35: 2712-9.
63. [63] Lopez-Castejon G and Pelegrin P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs 2012; 21: 995-1007.
64. [64] Wang Y, Zhao X, Liu L. Clopidogrel with aspirin in acute minor stroke or transient ischemic Attack. N Engl J Med 2013; 369: 11-9.
65. [65] Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, Ikeda U. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011; 123: 594-604.
66. [66] Gao J, Chen C, Chen JX, Wen LM, Yang GL, Duan FP, Huang ZY, Li DF, Yu DR, Yang HJ, Li SJ. Synergism and rules of the new combination drug Yiqijiedu formulae (YQJD) on ischemic stroke based on amino acids (AAs) metabolism. Sci Rep 2014; 4: 5149.
67. [67] Duncan JA, Bergstralh DT, Wang Y, Willingham SB, Ye Z, Zimmermann AG and Ting JP. Cryopyrin/NALP3 binds atp/datp, is an atpase, and requires atp binding to mediate inflammatory signaling. Proc Natl Acad Sci U S A 2007; 104: 8041-6.
68. [68] Coll RC, Robertson A, Butler M, Cooper M and O’Neill LA. The cytokine release inhibitory drug crid3 targets asc oligomerisation in the NLRP3 and aim2 inflammasomes. PLoS One 2011; 6: e29539.
69. [69] Thacker JD, Balin BJ, Appelt DM, Sassi-Gaha S, Purohit M, Rest RF and Artlett CM. NLRp3 inflammasome is a target for development of broad-spectrum anti-infective drugs. Antimicrob Agents Chemother 2012; 56: 1921-30.